Gary Boone – FDA EIR, Apr 3, 2018

An FDA inspection of Clinical Investigator Gary Boone, affiliated with Paradigm Research Inc. in San Diego, CA, took place from March 26 to April 3, 2018. This initial, high-priority assignment was conducted under Compliance Program 7348.811, focusing on a clinical trial supporting a New Drug Application. The inspection concluded with the issuance of a Form FDA 483, detailing significant objectionable conditions. Key violations included Dr. Boone's failure to adequately supervise the study, per 21 CFR 312.60. Informed consent for all 34 subjects reviewed was obtained by unauthorized clinical research coordinators, not Dr. Boone as delegated. Additionally, adverse event severity and intensity were entered into electronic case report forms by staff before the Principal Investigator's assessment for 11 subjects. Some events were improperly evaluated or assessed by unauthorized personnel. Protocol deviations were noted regarding subject procedures and inadequate dietary instructions. Furthermore, the inspection identified failures to maintain adequate and accurate case histories (21 CFR 312.62), with adverse event assessments documented prematurely or inaccurately reported to the sponsor. These observations highlight a lack of proper oversight and adherence to regulatory requirements for clinical investigations. Dr. Boone acknowledged reliance on staff for initial assessments. The Form FDA 483 requires a formal response addressing these deficiencies.